Clinically relevant discrepancies between different rheumatoid factor assays by Falkenburg, W.J.J. (Willem J.J.) et al.
Clin Chem Lab Med 2018; aop
Willem J.J. Falkenburg*, Helen J. von Richthofen, Jana Koers, Cas Weykamp,  
Marco W.J. Schreurs, Liesbeth E. Bakker-Jonges, Inez-Anne Haagen, Willem F. Lems,  
Dörte Hamann, Dirkjan van Schaardenburg and Theo Rispens*
Clinically relevant discrepancies between different 
rheumatoid factor assays
https://doi.org/10.1515/cclm-2017-0988
Received November 3, 2017; accepted December 14, 2017
Abstract
Background: Accurate measurements of rheumatoid 
factors (RFs), autoantibodies binding IgG, are important 
for diagnosing rheumatoid arthritis (RA) and for predict-
ing disease course. Worldwide, various RF assays are 
being used that differ in technique and target antigens. We 
studied whether assay choice leads to clinically important 
discrepancies in RF status and level.
Methods: RF measurements using four commercial RF 
assays were compared in 32 RF+ samples. Using enzyme-
linked immunosorbent assays (ELISAs), the influence 
of the target antigen source – human IgG (hIgG) versus 
rabbit IgG (rIgG) – on measured RF levels was investigated 
in arthralgia patients and RA patients.
Results: Substantial discrepancies were found between 
RF levels measured in the four commercial assays. Six 
samples (19%) with RF levels below or slightly above the 
cutoff in the rIgG-based Phadia assay were RF+ in three 
assays using hIgG as the target antigen, some with very 
high levels. Direct ELISA comparisons of RF reactivity 
against hIgG and rIgG estimated that among 173 ACPA+ 
arthralgia patients, originally RF negative in rIgG-based 
assays, up to 10% were single positive against hIgG. Mon-
oclonal RFs binding to hIgG and rIgG or hIgG only sup-
ported these findings. In a cohort of 69 early RA patients, 
virtually all RF responses reacted with both targets, 
although levels were still variable.
Conclusions: The use of RF assays that differ in technique 
and target antigen, together with the different specificities 
of RF responses, leads to discrepancies in RF status and 
levels. This has important consequences for patient care 
if RA diagnosis and disease progression assessments are 
based on RF test results.
Keywords: arthralgia; assays; rabbit IgG; rheumatoid 
arthritis; rheumatoid factor; target antigen.
Introduction
Rheumatoid factors (RFs) are autoantibodies that bind 
to epitopes within the constant region (Fc) of IgG. The 
first evidence for their existence was found in 1937 when 
sera from patients with rheumatoid arthritis (RA) were 
shown to cause agglutination of sheep red blood cells 
opsonized with rabbit IgG (rIgG) [1, 2]. Presently, both 
RF status and level are part of the classification crite-
ria for RA [3], and while the more recently discovered 
anti- citrullinated protein antibodies (ACPAs) have a 
higher specificity for RA [4, 5], RFs are still considered 
to have value in predicting development of disease in 
patients at-risk for RA and predicting disease course in 
RA patients [6–9].
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Many different assays are used in the clinic to detect 
RF. Nephelometry and turbidimetry assays are based on 
the originally observed phenomenon of RF-induced agglu-
tination of IgG-coupled particles [10]. Enzyme-linked 
immunosorbent assays (ELISAs), including manual or 
automatic assays such as the widely used EliA™ system 
(Phadia), use isotype-specific secondary antibodies to 
detect RF bound to coated IgG [11]. The use of these dif-
ferent assays for detection and quantification of RF intro-
duces potential sources of variability at multiple levels.
First, although ELISA-based assays specifically detect 
one RF isotype (IgM-, IgA- or IgG-RF), the exact contribu-
tion of the different RF isotypes to the agglutination meas-
ured in nephelometry and turbidimetry assays is unclear. 
Most likely, IgM-RFs are primarily responsible for the 
agglutination, as their polyvalent penta/hexameric struc-
ture makes them superior to IgA- and IgG-RF in crosslink-
ing IgG-Fcs [12]. It is even possible that IgG-RF and/or 
IgA-RF could have an inhibitory effect on agglutination by 
competing with IgM-RF for IgG-Fc binding sites.
Second, different assays use different sources of IgG 
as the target antigen to which the RFs bind. Some assays, 
including the Phadia EliA™ system, use rIgG, analogous 
to the experiments in which RF was first discovered. Other 
assays use human IgG (hIgG) or human Fc domains. 
Although rIgG contains a histidine residue at amino acid 
(aa) position 435 that is critical in the “Ga epitope”, which 
is an important binding site for RFs [13, 14], homology 
between rabbit and human CH2-CH3 domains is only 74%.
A third factor likely to cause intertest variability is the 
polyclonal and polyspecific nature of the RF response. 
Although some RF responses seem to have restricted reac-
tivity to one epitope on IgG-Fc, others are composed of 
various RF clones specific for different epitopes [15, 16].
Finally, the concentration of the target IgG-antigen 
used may influence measurement of RF levels. IgM-RFs 
are generally considered to be of low affinity compared 
to IgG antibodies against recall antigens [17, 18]. Their 
binding depends on making a polyvalent interaction with 
multiple target IgGs using multiple of their 10 (pentameric 
IgM) or 12 (hexameric IgM) antigen binding domains. At 
low concentrations of target IgG, with the IgG-Fcs too far 
apart to facilitate sufficiently multivalent interaction, only 
the higher affinity fraction of an RF response may bind. 
Two sera with the same amount of RF but different RF 
affinities may show the same level of RF in a test with a 
high target IgG density and yet significantly differ in a test 
with a low target density.
Because RF status and RF level can have clinical con-
sequences for diagnosing RA, predicting disease course 
and treatment determination [19, 20], it is essential to 
determine the extent of intertest variability between the 
different RF assays used in the clinic and to understand 
the causes of this variability. Here we analyze data from 
the Dutch Foundation for Quality Assessment in Medical 
Laboratories (SKML) comparing RF measurements 
between four internationally used RF assays each differ-
ing in technique, isotypes measured and target-IgG-anti-
gen used (Table 1). Furthermore, we examined in different 
clinical cohorts the occurrence of RF responses specific 
for hIgG that are potentially missed by RF assays using 
rIgG as the target antigen.
Materials and methods
RF measurements by commercial assays: analysis 
of  variation
For analysis of variation in RF measurements between different 
commercially available assays, 32 RF+ samples were selected from 
leftover sera that had been sent to Sanquin Diagnostics Services for 
RF testing. This panel included a wide range of RF levels as deter-
mined by an in-house IgM-RF ELISA: 19–837 IU/mL. For the in-house 
IgM-RF ELISA, 96-well flat-bottom plates coated with 25 μg/mL hIgG 
were used. Serum samples were put at 37 °C for 30 min, diluted in 
phosphate-buffered saline (PBS) supplemented with 0.1% Tween-20 
and incubated after washing the plates 4× 100 μL/well for 30  min 
(shaking) at room temperature. After washing, IgM-RF was detected 
by incubating the wells for 30 min with 100 μL horseradish peroxi-
dase (HRP)-conjugated mouse monoclonal antihuman IgM (μ-chain-
specific) antibodies diluted 1:1500 (0.5 mg/mL, MH15; Sanquin) and 
visualized with Uptima TMB ELISA peroxidase substrate (Interchim) 
Table 1: Characteristics of the RF assays.
Name and technique of RF assay Manufacturer Antigen RF Istoype
EliA™ RF IgM: Fluoroenzymimmunoassay Phadia Aggregated rabbit IgG IgM
RF II Tina-quant: Immunoturbidimetry Roche Human IgG-coated latex particles Total
AUTOSTAT II: ELISA HYCOR Human IgG IgM
Rate nephelometry Beckman Coulter Particle bound human IgG Total
Sanquin IgM RF ELISA Sanquin Human IgG IgM
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diluted 1:1  with distilled water. The reaction was stopped with 2  M 
H2SO4, and the optical density (OD) was read at 450 nm. IgM-RF lev-
els were calculated against a calibration curve of a reference sample 
(Reference Laboratory for Rheumatologic Serology [RELARES]) with 
a defined IgM-RF level of 200 IU/mL [21].
The 32 selected samples were aliquoted and sent to laboratories 
in the Netherlands that use different assays for RF testing (Table 1). 
All samples were tested in triplo on the Phadia EliA™ system and 
with HYCOR ELISAs at the Erasmus MC University Medical Center in 
Rotterdam, with immunoturbidimetry (Roche RF II Tina-quant) at the 
Onze Lieve Vrouwe Gasthuis in Amsterdam and with rate nephelom-
etry (Beckman Coulter) at the Queen Beatrix Hospital in Winterswijk.
Direct comparison of RF reactivity against hIgG and rIgG 
in ELISA
Nunc MaxiSorp 96-well flat-bottom plates (Thermo Scientific) were 
used for all ELISAs. Target antibodies – hIgG and rIgG – were diluted 
in PBS to 15 or 25 μg/mL, or 1 μg/mL for the experiments with mon-
oclonal RFs, and coated overnight at 4 °C. Polyclonal hIgG was 
obtained from Intravenous immunoglobulin (IVIG, Nanogam, San-
quin). Polyclonal rIgG was purified from rabbit plasma using protein 
G affinity chromatography (HiTrap Prot G HP; GE Healthcare Life Sci-
ences). After overnight coating, plates were washed 5× with 0.02% 
Tween 20-PBS. All subsequent washing steps were identical. One 
hundred microliters of serum samples, controls, monoclonal IgM-
RFs or reference serum diluted in 0.1% Tween 20-PBS was added to 
the wells and incubated for 30 min, shaking, at room temperature. 
After washing, IgM-RF was detected by incubating the wells for 
30  min with MH-15 and visualized with 3,3′,5,5′-tetramethylbenzi-
dine (100 μg/mL) in 0.11 M acetate buffer, pH 5.5, containing 0.003% 
H2O2 (Merck). The reaction was stopped with 2 M H2SO4, and OD was 
read at 450 nm and 540 nm for background correction using a BioTek 
microtiter plate reader. IgM-RF levels were calculated against a titra-
tion curve of the RELARES reference sample. For the hIgG-based ELI-
SAs, which are performed similarly to the Sanquin IgM-RF ELISA, the 
same cutoff of 19 IU/mL was used. Testing 54 healthy donor samples 
showed that using the same cutoff for the rIgG-based ELISAs results 
in the same percentage of positive samples (3.7%) as for the hIgG-
based ELISAs.
Serum samples used in the ELISAs
Three sets of serum samples were used in the ELISAs. The first set 
consisted of 51 leftover samples from sera that had previously tested 
RF+ using the in-house IgM-RF ELISA at Sanquin Diagnostic Services. 
This set excluded but was comparable to the set of 32 samples used 
for the comparison between the commercial assays. The second set 
of serum samples consisted of 173 ACPA+ arthralgia patients who 
originally tested RFneg. in an in-house IgM-RF ELISA or the Phadia 
EliA, both of which use rIgG as the target antigen. These samples 
were selected from a previously described [6] cohort of ACPA+ and/
or IgM-RF+ patients with (a history of) arthralgia recruited since 
2004 at the Jan van Breemen Research Institute, Reade (Amsterdam, 
The Netherlands). The third set consisted of 69 serum samples from 
disease-modifying antirheumatic drug (DMARD)-naïve RA patients 
based in the Amsterdam region. These patients fulfilled the 1987 RA 
classification criteria of the American College for Rheumatism (ACR) 
[22]. For all RA samples, the original RF assay was an in-house IgM-
RF ELISA with rabbit target-IgG. Both the hIgG-based original assay 
in the diagnostics cohort and the rIgG-based original assays in the 
patient cohorts introduce a selection bias. Samples with RF specific 
for rIgG but not hIgG would not have been included in the diagnos-
tics cohort; ACPAneg. patients with RF specific for hIgG but not rIgG 
would not have been included in the arthralgia cohort and would 
have had to score more points on other classification criteria to be 
diagnosed with RA and included in the RA cohort.
Ethics approval: Arthralgia patients and RA patients signed 
informed consent forms for use of their serum samples. No informed 
consent was obtained for the sera from Sanquin Diagnostic Services 
because these were the leftover samples from sera obtained for rou-
tine diagnostic purposes. These materials were used anonymously 
without any connection to clinical or patient-specific data. The study 
complies with the World Medical Association Declaration of Helsinki 
regarding ethical conduct of research involving human subjects.
Monoclonal IgM-RF: Two monoclonal IgM rheumatoid factors 
(mRFs), RF61 [17, 23] and RF-AN [24], were produced as described pre-
viously [18].
Results
Comparing RF levels determined with four 
commercial assays
To analyze intertest variability of RF measurements, RF 
levels were determined in 32 serum samples with four com-
mercially available techniques (Table 1) and plotted in xy 
graphs and Bland-Altman plots (Figure 1). All samples had 
previously been determined RF+ in an in-house IgM-RF 
ELISA at Sanquin Diagnostic Services, and the panel 
was selected to encompass a wide range of RF levels (19–
837  IU/mL, median 120  IU/mL). It is immediately appar-
ent that some samples are RFneg. in the Phadia assay but 
have high RF levels in the other three commercial assays 
and the Sanquin ELISA (Figure 1A, upper panels). The 
Table in Figure 1 shows that for six samples (18%), all four 
assays that use hIgG as the target antigen detected RF, also 
at high levels, whereas the rIgG-based Phadia detected 
levels below or just above its cutoff point. This suggests 
that some RF+ samples have an RF response that is specific 
for hIgG and cannot be detected in an assay that uses rIgG 
as the target antigen. The Bland-Altman plots in the lower 
panels show that apart from these Phadianeg. samples also 
many other samples had much higher levels in the other 
four assays. This is especially true for those with relatively 
low average levels, which was partly compensated by the 
lower cutoff value for positivity in the Phadia assay.
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Figure 1: Comparisons of RF levels measured with four commercial RF assays.
(A–B upper panels) RF levels determined in 32 RF+ samples with four commercial RF assays and the original in-house Sanquin IgM-RF ELISA, 
plotted in x-y graphs. One sample with an extremely high level in the Roche assay was excluded from the graphs. Samples below the dotted 
lines are considered RF negative in the respective assays. (A–B lower panels) Bland-Altman plots of the same data as in the upper panels. 
Samples outside the gray area showed a more than twofold difference in RF level between two assays. Table: RF levels for six samples with a 
large discrepancy between Phadia and the other four assays. Levels with white background are below the cutoff value of the respective assay.
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Although there appears to be a better correlation 
between RF levels measured with the different hIgG-based 
assays (Figure 1B), there was still substantial variation. 
No samples were found to be both positive in the assays 
detecting “total RF” (Beckman and Roche) and negative 
in both commercial assays that specifically detect IgM-RF 
(Phadia and HYCOR). This was expected, as the samples 
were selected from a panel of sera previously determined 
RF+ in the Sanquin ELISA that measures IgM-RF. Because 
it is likely that not all tested samples also had IgA- and/
or IgG-RF, the fact that there was only one sample RFneg. in 
the Roche assay and no samples in the Beckman assay sug-
gests that, in these turbidimetry and nephelometry assays, 
the IgM isotype is sufficient for causing the agglutination.
To test whether the discrepancies between the results 
from the different assays would also be found when pooled 
samples are used to compare assays, the 32 samples tested 
in Figure 1 were divided into quartiles based on their RF 
level, pooled and tested in the four commercial RF assays. 
Figure 2 shows that when comparing pooled samples, the 
discrepancies seen for the individual samples level out, 
seemingly improving agreement between the assays.
Comparison of RF reactivities to hIgG 
and rIgG
To further investigate the possibility that the RF response 
has a strong preferential binding to hIgG over rIgG in 
certain individuals, a direct comparison of RF reactivity 
against the two targets was performed for the additional 
51 RF+ samples sent to Sanquin Diagnostic Services for 
RF testing (the diagnostics cohort). The majority of these 
samples showed comparable reactivity against both 
targets in ELISA (Figure 3A). Some samples, especially 
among those with lower RF levels, bound much better to 
hIgG than rIgG. Conversely, there were no samples with 
substantially higher reactivity against rIgG. Because we 
do not have access to the clinical data of this cohort, we 
cannot determine which samples came from RA patients.
To determine if hIgG- or rIgG-specific RF responses 
also influence RF status and/or levels in better defined (at 
risk for-) RA cohorts, the same direct ELISA comparison of 
RF reactivity against hIgG and rIgG was performed in two 
patient cohorts. The first cohort consisted of patients with 
(a history of) arthralgia, i.e. joint pain but no clinical arthri-
tis, tested positive for ACPA and/or IgM-RF originally deter-
mined in rIgG-based assays. From this cohort 173 ACPA+ 
RFneg. patients were selected and re-tested for RF reactiv-
ity against hIgG and rIgG. Figure  3B shows that reactiv-
ity against hIgG was higher than what would be expected 
for this patient group, which had originally tested RFneg.. 
Although most of the samples with reactivity above the 
cutoff for positivity in the ELISA with hIgG targets (x-axis) 
also showed reactivity against rIgG (y-axis), a consider-
able proportion of the total cohort – 18/173 (10.4%) – 42% 
of the anti-hIgG RF+ samples, showed substantially higher 
(>2 ×) reactivity against hIgG than against rIgG. This is not 
only true for samples with very low levels, where small 
absolute differences translate into large ratio differences 
in the Bland-Altman plots (Figure 3B, lower panel), but 
also for samples with anti-hIgG RF levels well above the 
cutoff. This suggests that these samples may have been 
incorrectly classified as RFneg. because their RF response is 
specific for hIgG. Indeed, if we use the 19 U/mL cutoff also 
for the rIgG-based ELISAs, 10% of samples (18/173) would 
be classified anti-hIgG positive anti-rIgG negative.
Next, we analyzed RF reactivities in 69 DMARD-naïve 
patients with active early RA, either RFneg. or RF+ in their 
initial rIgG-based RF assay. In contrast to the diagnostics 
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Figure 2: Discrepancy between assays for individual versus pooled samples.
The 32 samples tested in the four commercial RF assays – representative example in (A) – were divided into quartiles based on their RF level, 
pooled and also tested in the four RF assays – representative example in (B). For reference, a straight (dotted) line was fitted through the 
data points with nonlinear regression.
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cohort and the arthralgia cohort, few RA patients showed 
a large discrepancy between RF reactivity against hIgG 
and rIgG (Figure 3C), only one or two originally classified 
RFneg. samples shows high anti-hIgG reactivity with low 
anti-rIgG reactivity and one RF+-assigned sample shows 
the opposite pattern.
To further substantiate possible hIgG specific-
ity of RFs, we tested target-specific binding of two 
recombinantly produced monoclonal IgM-RFs originally 
isolated from two RA patients [23–26]. Monoclonal RF-AN 
was reported to bind an epitope at the CH2-CH3 interface 
of IgG, with an important role for His435 [24, 27], which is 
identical in hIgG and rIgG. Regarding the contact residues 
between RF-AN and hIgG1, there is just one amino acid dif-
ference with rIgG, within the 15 aa comprising the epitope. 
By contrast, RF61 binds hIgG at epitopes in the CH3 
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Figure 4: Binding profiles of two monoclonal IgM-RFs.
Binding to rIgG and hIgG was analyzed in ELISAs for two recombinantly produced monoclonal IgM-RFs originally isolated from RA patients, 
RF-AN (A) and RF61 (B) at different concentrations of mRF. OD, optical density.
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Figure 3: Direct comparison of IgM-RF reactivity against rabbit IgG and human IgG in three cohorts.
ELISAs with rabbit IgG or human IgG as coated target antigen were used to directly compare IgM-RF reactivity against these targets in three 
cohorts: (A) 51 samples sent to Sanquin Diagnostic Services for RF testing, all originally tested RF+ in a human IgG-based IgM-RF ELISA (diag-
nostics cohort). (B) 173 ACPA+ patients with (a history of) arthralgia, originally tested RFneg. in rabbit IgG-based IgM-RF assays. (C) 69 DMARD-
naïve RA patients, originally RF+ or RFneg. in rabbit IgG-based assays, with active early RA diagnosed according to the 1987 ACR criteria (RA 
cohort). For every cohort samples tested positive in the original (cohort-specific) RF assays are represented by black dots, negative samples 
by blue dots. AU, arbitrary units; IU, international units; rIgG, rabbit IgG; hIgG, human IgG. Straight lines: x = y. Vertical dotted lines: cutoff 
of hIgG-based IgM-RF ELISA.
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domains, close to the C-terminus [17]. Arg355 is crucial for 
RF binding, and although conserved in rIgG, there are four 
residue differences at the interaction interface with the 
IgG-CH3 domains out of a total of 13 Fc contact residues. 
As illustrated in Figure 4, monoclonal RF-AN binds hIgG 
and rIgG equally well, whereas monoclonal RF61 binds to 
hIgG but not to rIgG. Although it is unknown what per-
centage of the RF response comprises these individual RF 
clones, the results show that RFs binding both targets or 
only hIgG can be present in RA patients.
Discussion
RF status and level are important factors in the most 
recent classification criteria for RA [3]. The presence of RF 
is a predictor for the development of RA in at-risk individ-
uals, signals a more severe disease course in RA patients 
and can influence treatment decisions. Here we show 
that there can be large discrepancies in measured levels 
between commercial RF assays and even disagreement on 
whether individual samples are RF positive. The choice of 
the target antigen, human versus rabbit IgG, was identified 
as one important potential cause of this disagreement. In 
a cohort selected on IgM-RF reactivity against hIgG, mul-
tiple samples with low or undetectable reactivity against 
rIgG were identified. These would likely be incorrectly 
classified as RFneg. in rIgG-based assays. Because rIgG- and 
hIgG-based assays have not been compared head to head 
on clinical value, we cannot yet determine the clinical con-
sequences of missing these hIgG-specific RF responses. It 
is clear however that diagnostic and therapeutic decisions 
based on RF results will be affected.
Problems with comparability between RF levels deter-
mined with nephelometry and turbidimetry were reported 
previously by Ameratunga et  al. [28]. Van der Linden 
showed that RF levels measured in two high-level samples 
varied considerably between ELISA and nephelometry 
and turbidimetry and between different labs using the 
same method [29]. Comparing enzyme immunoassays, 
large discrepancies in qualitative as well as quantitative 
RF test results have been reported. A study by Bas et al. 
[30] found the same qualitative result in only 33% of 
samples when six IgM-RF ELISAs were compared. Agree-
ment was 51% and 61% when results were stratified for the 
three rIgG- and the three hIgG-based assays. The authors 
concluded that quantitative results could not be com-
pared across assays. This conclusion is supported by our 
data that show substantial discrepancies when compar-
ing RF levels measured in the different commercial assays. 
There is disagreement on RF positivity in five samples 
(17%). Similar to the experiments described in the present 
study, Bas et al. also performed a direct comparison for RF 
reactivity against rabbit and human target antigen, using 
rFc and hFc instead of the entire IgG molecule. Reported 
sensitivity was slightly higher for IgM-RF and significantly 
higher for IgA-RF when using hFc compared to rFc.
Because RFs are classified as autoantibodies, one 
would expect that testing for RF reactivity against hIgG 
has more value than against rIgG. An early study by Tuomi 
[31] found that the RF response in most RA patients bound 
both hFc and rFc in ELISA. However, some RA sera (4/93) 
that were RFneg. in agglutination tests using rIgG as well 
as in ELISAs with rFc did bind to hFc. Conversely, 3/37 RA 
sera with a positive agglutination test recognized only rFc, 
albeit at low levels. Notably, in non-RA subjects, Tuomi 
found a much larger proportion to be single+ for rFc or 
hFc when retested against both targets. The data from the 
present study are in line with these earlier results. In the 
diagnostics cohort (Figure 3A), most likely a mix of early 
RA patients and non-RA subjects, a significant proportion 
of the samples contains an RF response that binds much 
better to hIgG than to rIgG. From the arthralgia cohort, we 
retested the subgroup that was ACPA+ and RFneg. accord-
ing to the original rIgG-based RF tests used for this cohort. 
We expected a better chance to find missed hIgG-specific 
RF responses in this group than in the originally ACPAneg. 
RFneg. arthralgia patients group because ACPA and RF 
often co-occur [32]. Some samples showed high reactiv-
ity against both hIgG and rIgG when retested. This may 
have been due to errors in the original RF assay or could 
have been caused by differences in the method of prep-
aration of the rIgG, method of coating the rIgG (directly 
versus biotinylated rIgG on streptavidin-coated plates) or 
by differences in coating concentration. Strikingly, a sub-
stantial proportion of the arthralgia patients showed high 
anti-hIgG RF reactivity with low or almost no detectable 
anti-rIgG RF reactivity (Figure 3B). We estimate that up 
to 10% of these patients could have an anti-rIgG negative 
but anti-hIgG positive RF test result. It is important to note 
that the cutoff for anti-rIgG reactivity was not extensively 
validated for our assays and that these results cannot be 
directly translated into discrepancies between other rIgG- 
and hIgG-based assays.
Accurately classifying RF status is important in the 
arthralgia patient group because RF positivity is associ-
ated with a higher risk of progressing from arthralgia to 
RA in ACPA+ patients [6, 8]. The early RA cohort, consist-
ing exclusively of confirmed RA cases included based 
on the presence of bad prognostic factors, showed reac-
tivity between virtually all RF+ samples and both targets 
(Figure  3C). Still, many samples showed higher levels 
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against hIgG, with six anti-hIgG+ samples showing RF 
levels >2 ×  higher against hIgG than against rIgG. Based 
on the data obtained in the RA cohort that shows just 
one sample with much lower anti-hIgG than anti-rIgG RF 
reactivity, the risk of false positivity appears low when 
using rIgG as the target antigen. Instead, the data from 
the diagnostics cohort and the arthralgia cohort, showing 
RF responses with much higher anti-hIgG than anti-rIgG 
RF reactivity, indicate that there is a significant risk of 
false negativity especially among samples with relatively 
low RF levels. However, it may not be justified to speak of 
“false positivity” and “false negativity” until the clinical 
value of hIgG- and rIgG-specific RF responses has been 
determined. Using a hIgG-based assay with potentially 
higher sensitivity would be important particularly in the 
arthralgia phase, as discussed above.
The fact that, in all three cohorts, samples that show 
equal RF reactivity against hIgG can differ extensively 
in reactivity against rIgG suggests that RF responses can 
contain a mix of RF clones that recognize both targets and 
clones that solely recognize hIgG. This was further illus-
trated by monoclonal IgM-RF RF-AN reacting with both 
targets and RF61 exclusively reacting with hIgG (Figure 4). 
A number of previous studies [33–35] describe monoclonal 
RFs with restrictive reactivity against hIgG, whereas few 
studies suggest the presence of monoclonal RFs that bind 
to rIgG but not hIgG [36, 37]. When hIgG-specific RF clones 
such as RF61 constitute a large part of an RF response, 
measured levels will be much lower in rIgG-based assays. 
RF responses consisting exclusively of such RF clones 
will go undetected in rIgG-based assays. Misclassifying a 
patient with such an RF response as RFneg. can have real-
life consequences in the clinic and it is therefore impor-
tant that both clinical chemists and rheumatologist are 
aware of this issue.
The findings presented here also have important 
implications for harmonization of RF assays. The RF 
response is a very polyspecific response, and differ-
ent individuals will have a different mix of RFs compos-
ing their RF response, with distinct contributions of RFs 
binding rIgG and/or hIgG and RFs binding with high or 
low affinity. Every assay detects these distinct character-
istics of an RF response differently. The resulting discrep-
ancies between assays are only detected when individual 
samples are compared between the assays, as has been 
done in the present study. When pooled samples are used 
to compare assays, these discrepancies level out, and are 
therefore overlooked, as illustrated in Figure 2. Here the 
32 samples tested in Figure 1 were divided into quartiles 
based on their RF level, pooled and tested in the four RF 
assays. It is clear from Figure 2B that the pools give much 
better agreement between the assays. These data show 
that at the current state of art, harmonization is feasible 
for pooled sera, but not for individual samples. Articles 
referring directly or indirectly to RF should report the 
characteristics of the assay used for the measurements 
[38], and authors should be aware that both qualitative 
and quantitative results cannot be reliably compared 
across different assays.
In conclusion, there is substantial discrepancy in 
detected RF levels between the different RF assays used in 
the clinic. This is clinically relevant because the discrepan-
cies are large enough to affect classification of RA using the 
ACR/EULAR classification criteria and can affect diagnosis 
of RA patients, prediction of their disease course and treat-
ment decisions (if dependent on RF levels). Others have 
suggested ignoring RF level and looking solely at RF status 
[29], or leaving out the RF test in the work-up of a suspected 
RA patient [39]. We propose to focus on improving RF tests 
by further dissecting the RF response to identify the clini-
cally most relevant RF reactivities. The next step could be 
validation of our findings in other cohorts from different 
countries, followed by international consensus meetings 
about standardization of RF tests. Eighty years after the 
first RF tests by Waaler, the rheumatology field should col-
laborate in the optimization of this still valuable test.
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